Anti-SARS-CoV-2 Monoclonal Antibodies

Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection. The mAb treatment is usually offered at an infusion center because the treatment is given through an intravenous (IV) infusion or shots.

sotrovimab
Bamlanivimab plus etesevimab
Evusheld (aka AZD7442)
Casirivimab plus imdevimab

The SARS-CoV-2 genome encodes 4 major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as nonstructural and accessory proteins. The spike protein is further divided into 2 subunits, S1 and S2, that mediate host cell attachment and invasion. Through its receptor-binding domain (RBD), S1 attaches to angiotensin-converting enzyme 2 (ACE2) on the host cell; this initiates a conformational change in S2 that results in virus-host cell membrane fusion and viral entry. Often, anti-SARS-CoV-2 monoclonal antibodies (mAbs) target the spike protein.

Back to top